Health Highlights: Aug. 26, 2009

HealthDay SHARE

"Our biggest concern is early-life-stage development," NRDC senior scientist Jennifer Sass told the Post. "If there's a disruption during that time, it becomes hard-wired into the system. These endocrine disrupters act in the body at extremely low levels. These spikes matter."

Her group noted that the EPA's own analysis found that during 2003 and 2004, 54 water systems had peaks of atrazine concentrations that exceeded the 3 parts per billion the agency considers safe.

Speaking to the Post, Steve Owens, the administrator of the EPA Office of Prevention, Pesticides and Toxic Substances, said the agency "will take a hard look at atrazine and other substances."

A spokesman for the herbicide industry told the Post the NRDC report was alarmist. "Atrazine is one of the best studied, most thoroughly regulated molecules on the planet," said toxicologist Tim Pastoor, who works for atrazine maker Syngenta. "Those momentary spikes are not going to be injurious to human health."

-----

Many Doctors Unfamiliar With 'Off-Label' Use of Drugs: Report

It's called "off-label" use, and it's a practice that allows doctors to prescribe drugs for purposes not specifically approved by the U.S. Food and Drug Administration. But a new survey found that many physicians might not know when they are prescribing a drug "off label," The New York Times reported.

The typical doctor surveyed was able to identify the correct FDA approval status for only about half the drugs on a list provided by the researchers, according to a study in the journal Pharmacoepidemiology and Drug Safety, the newspaper said.

The greatest confusion surrounded psychiatric drugs, the survey of some 600 doctors found. Nearly 20 percent who had prescribed Seroquel (quetiapine) in the previous year thought it was FDA-approved for dementia and agitation. But the drug was never approved for such use and even carries a "black box" warning that it can be dangerous for elderly patients with dementia. And 33 percent of doctors who had used lorazepam (often marketed as Ativan) to treat chronic anxiety thought it had FDA approval for this use. But, the FDA warns against using it for this purpose, the Times said.

Copyright © 2011 HealthDay. All rights reserved.